benzyloxycarbonylleucyl-leucyl-leucine-aldehyde and Pheochromocytoma

benzyloxycarbonylleucyl-leucyl-leucine-aldehyde has been researched along with Pheochromocytoma* in 1 studies

Other Studies

1 other study(ies) available for benzyloxycarbonylleucyl-leucyl-leucine-aldehyde and Pheochromocytoma

ArticleYear
Prolonged treatment with the proteasome inhibitor MG-132 induces apoptosis in PC12 rat pheochromocytoma cells.
    Scientific reports, 2022, 04-06, Volume: 12, Issue:1

    Rat pheochromocytoma (PC12) cells were treated with the proteasome inhibitor MG-132 and morphological changes were recorded. Initially, neuronal differentiation was induced but after 24 h signs of morphological deterioration became apparent. We performed nuclear staining, flow cytometry and WST-1 assay then analyzed signal transduction pathways involving Akt, p38 MAPK (Mitogen-Activated Protein Kinase), JNK (c-Jun N-terminal Kinase), c-Jun and caspase-3. Stress signaling via p38, JNK and c-Jun was active even after 24 h of MG-132 treatment, while the survival-mediating Akt phosphorylation declined and the executor of apoptosis (caspase-3) was activated by that time and apoptosis was also observable. We examined subcellular localization of stress signaling components, applied kinase inhibitors and dominant negative H-Ras mutant-expressing PC12 cells in order to decipher connections of stress-mediating pathways. Our results are suggestive of that treatment with the proteasome inhibitor MG-132 has a biphasic nature in PC12 cells. Initially, it induces neuronal differentiation but prolonged treatments lead to apoptosis.

    Topics: Adrenal Gland Neoplasms; Animals; Apoptosis; Caspase 3; Enzyme Activation; JNK Mitogen-Activated Protein Kinases; Leupeptins; p38 Mitogen-Activated Protein Kinases; PC12 Cells; Pheochromocytoma; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Rats

2022